JP-2022514950-A5 -

Dates

Publication Date

20221226

Application Date

20191219

Description

Additional embodiments of the present invention are shown in the following sections and claims. [Section 1] (i) an anti-IL-36 antibody comprising a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3), and/or (ii) a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3), (a) HVR-L1 contains an amino acid sequence selected from TGSSSNIGAHYDVH (SEQ ID NO: 18), TGSSSNIGAGYDVH (SEQ ID NO: 22), RASQSVSSNYLA (SEQ ID NO: 38), or RASQTIYKYLN (SEQ ID NO: 42), (b) HVR-L2 comprises an amino acid sequence selected from SNNNRPS (SEQ ID NO: 15), GNDNRPS (SEQ ID NO: 19), GNTNRPS (SEQ ID NO: 23), GRNRPS (SEQ ID NO: 27), SASSLQS (SEQ ID NO: 39), or AASSLQS (SEQ ID NO: 43), (c) HVR-L3 contains an amino acid sequence selected from QSYDYSLRGYV (SEQ ID NO: 16), QSYDYSLSGYV (SEQ ID NO: 20), QSYDYSLRVYV (SEQ ID NO: 28), QSYDYSLKAYV (SEQ ID NO: 32), QSYDISLSGWV (SEQ ID NO: 36), QQTYSYPPT (SEQ ID NO: 40), or QQSSIPYT (SEQ ID NO: 44), (d) HVR-H1 is SAYAMHW (SEQ ID NO: 46), STSSYYW (SEQ ID NO: 50), SSTSYYW (SEQ ID NO: 54), GSRSYYW (SEQ ID NO: 58), STYAMSW (SEQ ID NO: 62), TSSNYYW (SEQ ID NO: 66), SSYGMH (SEQ ID NO: 70), SNYAIS (SEQ ID NO: 74), TSTNYYW (SEQ ID NO: 82), TSSNAYW (SEQ ID NO: 86), TASNYYW (SEQ ID NO: 90), TASNTYW (SEQ ID NO: 106), SDSSYYW (SEQ ID NO: 122), SESSYYW (SEQ ID NO: 126), STSSDYW (SEQ ID NO: 130), SNSSYYW (SEQ ID NO: 134), STSSYHW (SEQ ID NO: 142), SRSSYYW (SEQ ID NO: 146), XXXNXYX (SEQ ID NO: 251) (where the 1st place is X is T, D, E or N; the second X is S, A, E, G, K, Q, R or T; the third X is S, A, D, E, G, N, P, Q or T; the fifth X is Y, A, E, G, H, M, N, Q, S, T or V; the seventh X is W, F, I, V or Y) or XXXXXXW (Sequence ID 336) (where the first X is S or D) The amino acid sequence includes an amino acid sequence selected from: ; X at position 2 is T, A, D, E, G, H, K, N, P, Q, R, or S; X at position 3 is S, D, E, G, K, N, P, or R; X at position 4 is S, G, K, N, or P; X at position 5 is Y, A, D, E, G, H, M, N, Q, S, T, V, or W; X at position 6 is Y, A, F, G, H, M, N, or Q) (e) HVR-H2 is VISYDGTNEYYAD (SEQ ID NO: 47), SIYYTGNTYYNP (SEQ ID NO: 51), SIHYSGNTYYNP (SEQ ID NO: 55), SIHYSGTTYYNP (SEQ ID NO: 59), GISGGSGYTYYAD (SEQ ID NO: 63), SIDYTGSTYYNP (SEQ ID NO: 67), VISYGGSERYYAD (SEQ ID NO: 71), GILPILGTVDYAQ (SEQ ID NO: 75), NIDYTGSTYYNA (SEQ ID NO: 83), SIDYTGSTAYNP (SEQ ID NO: 87), SIDYTGSTYYNT (SEQ ID NO: 91), SI DYTGSTYYEP (SEQ ID NO: 99), SIDYTGSTYYEP (SEQ ID NO: 103), SIDYTGSTYYQP (SEQ ID NO: 119), SIYYTGNTYYNS (SEQ ID NO: 123), SIYYTGNTYYLP (SEQ ID NO: 131), SIYYTGNTYYMP (SEQ ID NO: 143), SIYYTGNTYYWP (SEQ ID NO: 147), SIYYTGETYYAP (SEQ ID NO: 151), XXDXXXXXXYXX (SEQ ID NO: 284) (where X at position 1 is S, N or T; X at position 2 is I, M or V; X at position 4 is Y or H; 5 The first X is T, H, L, or N; the sixth X is G, A, D, E, H, K, N, Q, R, S, or T; the seventh X is S, A, D, Q, or T; the eighth X is T, A, D, or E; the ninth X is Y, A, F, Q, S, or W; the eleventh X is N, D, E, H, P, or Q; the twelfth X is P, A, or E) or XXXXXXXXXYXP (Sequence ID 379) (where the first X is S, F, I, M, or Q; the second X is I, A, G, L, R, S, T, or V; the third X is Y, A, D, E, F The amino acid sequence comprises an amino acid sequence selected from: , G, H, K, L, M, N, P, Q, R, S, T or W; X at position 4 is Y, A, D, E, F, G, H, K, N, P, Q, R, S, T or W; X at position 5 is T, D, E, K, N, P or Q; X at position 6 is G or Q; X at position 7 is N, D, E, G, H, I, K, M, P, R or S; X at position 8 is T, A, E, F, G, H, K, P, Q, R, S, V, W or Y; X at position 9 is Y or W; X at position 11 is N, A, D, E, K, L, M, P, Q, S or T) (f) HVR-H3 is ARGIRIFTSYFDS (SEQ ID NO: 48), ARVRYGVGVPRYFDP (SEQ ID NO: 52), ARVHYGGYIPRRFDH (SEQ ID NO: 56), ARVAPSYPRVFDY (SEQ ID NO: 60), ARVVTYRDPPASFDY (SEQ ID NO: 64), ARGKYYETYLGFDV (SEQ ID NO: 68), AREPWYSSRGWTGYGFDV (SEQ ID NO: 72), AREPWYRLGAFDV (SEQ ID NO: 76), ATGKYYETYLGFDV (SEQ ID NO: 76) Number 84), AHGKYYETYLGFDV (Sequence ID 88), ATGSYYETYLGFDV (Sequence ID 100), ATGNYYETYLGFDV (Sequence ID 104), ASGKYYETYLGFDV (Sequence ID 112), ARGNYYETYLGFDV (Sequence ID 120), AGVRYGVGVPRYFDP (Sequence ID 128), SRVRYGVGVPRYFDP (Sequence ID 132), VRVRYGVGVPRYFDP (Sequence ID 144), TRVRYGVGVPRYFDP ( SEQ ID NO: 148), ARLRYGVGVPRYFDP (SEQ ID NO: 152), ARVKYGVGVPRYFDP (SEQ ID NO: 156), ARVRYGVGVPRHFDP (SEQ ID NO: 160), AXGXYYXTYLGFDV (SEQ ID NO: 322) (where X at position 2 is R, A, E, G, H, M, N, Q, S, T or Y; X at position 4 is K, A or S; X at position 7 is E or T) or XXXXXGXXVPRXFDP (SEQ ID NO: 462) (where X at position 1 is A The amino acid sequence includes an amino acid sequence selected from the following: (where X is V; the X at position 2 is R, A, G, N, Q, or T; the X at position 3 is V, A, F, I, K, L, M, Q, or S; the X at position 4 is R, A, I, K, L, M, P, Q, S, T, or V; the X at position 5 is Y,